Home
Approach
Product
About
News
Contact
News
Altis in the
news
.
Follow our journey to improving patient outcomes.
Filter
All
Announcements
Publications
Media Coverage
Altis Labs teams up with Hamilton Health Sciences on AI for Breast Cancer
Altis Labs teams up with Hamilton Health Sciences on AI for Breast Cancer
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
ESMO: AI-Based Prognostication from Baseline CT Scans in a Phase 3 Advanced Non-Small Cell Lung Cancer Trial
ESMO: AI-Based Prognostication from Baseline CT Scans in a Phase 3 Advanced Non-Small Cell Lung Cancer Trial
ESMO: Evaluation of Imaging-Based Prognostication (IPRO) for Advanced Non-Small Cell Lung Cancer Using Deep Learning Applied to CT Scans
ESMO: Evaluation of Imaging-Based Prognostication (IPRO) for Advanced Non-Small Cell Lung Cancer Using Deep Learning Applied to CT Scans
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
Axios: Clinical trial startup seeds $6M to speed research
Axios: Clinical trial startup seeds $6M to speed research
Previous
Next
Altis Labs Raises US$25 Million Series A Co-Led by OrbiMed and Qiming Venture Partners USA to Accelerate Clinical Development with AI Endpoints
Altis Labs AI Imaging Endpoint Predicts Overall Survival Benefit in Phase 3 Lung Cancer Trial: Data Presented at IASLC WCLC 2026
Altis Labs Announces Collaboration with Johnson & Johnson Innovative Medicine to Accelerate Clinical Development with AI
Altis Labs Announces Presentation of Results at ASCO 2025 Demonstrating IPRO-Δ Outperforms RECIST in Predicting Overall Survival in Phase 3 Trial
Altis Labs Partners with UHN on Multi-Year Collaboration to leverage AI in Cancer Imaging
Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
Altis Labs Announces Presentation of AI Model Evaluation on Data from Phase 3 Lung Cancer Trial at ELCC 2025
Altis Labs teams up with Hamilton Health Sciences on AI for Breast Cancer
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Next
IASLC WCLC: IPRO Response Rate detected treatment effects missed by ORR in MARIPOSA, a Phase 3 trial in EGFR-mutated aNSCLC
ASCO: Depth of IPRO-α response at week 8 is associated with progressively longer OS in advanced NSCLC patients treated with first-line pembrolizumab monotherapy
AACR: IPRO stratifies OS with greater prognostic discrimination than TNM substage in metastatic CRC.
ESMO: AI-Based Quantification of Longitudinal Body Composition Changes Shows Prognostic Associations in aNSCLC Patients in Real-World Data
ESMO: IPRO Response Rate Correlates More Strongly With OS Treatment Effects Than RECIST Objective Response Rate
CBCS: IPRO is generalizable to breast cancer, and provides higher discrimination of OS compared to TNM staging and age
ASCO: IPRO-Δ Predicts Overall Survival at Week 13, Outperforming RECIST in Phase 3 Trial
ISPOR: Real-World Digital Twins Replicate Control Arm Outcomes
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
Next
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
Axios: Clinical trial startup seeds $6M to speed research
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.jpg)
